Literature DB >> 8029025

Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure.

R Bergan1, Y Connell, B Fahmy, E Kyle, L Neckers.   

Abstract

Protein tyrosine kinases play key roles in cellular physiology. Specific inhibitors of these enzymes are important laboratory tools and may prove to be novel therapeutic agents. In this report we describe a new class of tyrosine kinase inhibitor, synthetic oligodeoxynucleotides (ODNs). An ODN is described which specifically inhibits p210bcr-abl tyrosine kinase autophosphorylation in vitro with a Ki of 0.5 microM. Inhibition is non-competitive with respect to ATP. The effects upon inhibitory activity of ODN structure modifications are described. The inhibition described is not mediated by classical antisense mechanisms and represents an example of the recently recognized aptameric properties of ODNs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8029025      PMCID: PMC308134          DOI: 10.1093/nar/22.11.2150

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  36 in total

1.  Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.

Authors:  M L Gishizky; O N Witte
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

Review 2.  Signalling targets for anticancer drug development.

Authors:  G Powis
Journal:  Trends Pharmacol Sci       Date:  1991-05       Impact factor: 14.819

Review 3.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.

Authors:  W J Gullick
Journal:  Br Med Bull       Date:  1991-01       Impact factor: 4.291

4.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin.

Authors:  L C Bock; L C Griffin; J A Latham; E H Vermaas; J J Toole
Journal:  Nature       Date:  1992-02-06       Impact factor: 49.962

5.  Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members.

Authors:  S K Hanks; A M Quinn
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

6.  Assay of cyclic AMP by protein kinase activation.

Authors:  S E Mayer; J T Stull; W B Wastila; B Thompson
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

7.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.

Authors:  A M Pendergast; A J Muller; M H Havlik; Y Maru; O N Witte
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

9.  Definition of a consensus sequence for peptide substrate recognition by p44mpk, the meiosis-activated myelin basic protein kinase.

Authors:  I Clark-Lewis; J S Sanghera; S L Pelech
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

10.  RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.

Authors:  C Tuerk; S MacDougal; L Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more
  8 in total

1.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Antisense approaches to the gene therapy of cancer--'Recnac'.

Authors:  I Gibson
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation.

Authors:  Y Liu; E Kyle; R Lieberman; J Crowell; G Kellof; R C Bergan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.

Authors:  P T Rowley; B A Kosciolek; E T Kool
Journal:  Mol Med       Date:  1999-10       Impact factor: 6.354

5.  Antisense oligodeoxynucleotide inhibition of delta protein kinase C expression accelerates induced differentiation of murine erythroleukaemia cells.

Authors:  A Pessino; M Passalacqua; B Sparatore; M Patrone; E Melloni; S Pontremoli
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

6.  Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.

Authors:  T Albrecht; R Schwab; C Peschel; H J Engels; T Fischer; C Huber; W E Aulitzky
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

7.  Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity.

Authors:  J Y Maltese; H W Sharma; L Vassilev; R Narayanan
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

8.  Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.

Authors:  T Skorski; M Nieborowska-Skorska; K Campbell; R V Iozzo; G Zon; Z Darzynkiewicz; B Calabretta
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.